Trexquant Investment LP acquired a new stake in Codexis, Inc. (NASDAQ:CDXS – Get Rating) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,571 shares of the biotechnology company's stock, valued at approximately $142,000.

A number of other institutional investors have also modified their holdings of the company. Bank of New York Mellon Corp raised its position in shares of Codexis by 0.7% in the first quarter. Bank of New York Mellon Corp now owns 220,879 shares of the biotechnology company's stock valued at $4,554,000 after buying an additional 1,618 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Codexis in the first quarter valued at approximately $33,000. Dana Investment Advisors Inc. grew its holdings in Codexis by 11.4% in the first quarter. Dana Investment Advisors Inc. now owns 25,034 shares of the biotechnology company's stock valued at $516,000 after purchasing an additional 2,554 shares during the period. Royal Bank of Canada grew its stake in Codexis by 14.2% during the first quarter. Royal Bank of Canada now owns 21,891 shares of the biotechnology company's stock worth $451,000 after buying an additional 2,721 shares during the period. Finally, AlphaCrest Capital Management LLC grew its stake in Codexis by 15.3% during the first quarter. AlphaCrest Capital Management LLC now owns 25,027 shares of the biotechnology company's stock worth $516,000 after buying an additional 3,321 shares during the period. Institutional investors and hedge funds own 99.04% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. StockNews.com upgraded shares of Codexis from a "sell" rating to a "hold" rating in a research note on Wednesday, November 23rd. HC Wainwright decreased their price objective on shares of Codexis from $25.00 to $15.00 and set a "buy" rating for the company in a research note on Monday, November 7th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $19.67.

Insider Activity at Codexis

Codexis Trading Up 0.7 %

Shares of CDXS stock opened at $5.67 on Monday. The company has a market capitalization of $372.45 million, a PE ratio of -11.81 and a beta of 1.45. The firm has a fifty day simple moving average of $5.68 and a 200-day simple moving average of $7.72. Codexis, Inc. has a twelve month low of $4.81 and a twelve month high of $35.35.

Codexis (NASDAQ:CDXS – Get Rating) last posted its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.03. The firm had revenue of $34.47 million for the quarter, compared to analysts' expectations of $31.41 million. Codexis had a negative net margin of 23.49% and a negative return on equity of 19.59%. Equities research analysts predict that Codexis, Inc. will post -0.5 EPS for the current year.

Codexis Company Profile

(Get Rating)

Codexis, Inc discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.

Featured Articles

• Get a free copy of the StockNews.com research report on Codexis (CDXS)
• Is Salesforce Stock a Bargain Down Here?
• Intel is a Sleeping Giant Ready to Awaken
• Why CSL Ltd Stock Could Be Worth a Look
• MarketBeat: Week in Review 11/28 – 12/02
• Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?

Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXS – Get Rating).

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.